Nu Skin Enterprises, Inc.
$3.80+$0.03 (+0.8%)
Last close · Data as of Nov 20, 2026
- Market cap
- $258.3M
- P/E
- 1.6x
- EV / EBITDA
- 1.2x
- Revenue
- $1.5B
- Net margin
- 10.8%
- ROCE
- 20.4%
Price chart
Technical chartScreen technicals →-59.9% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- -23.7%
- 3M
- -18.3%
- 6M
- -34.9%
- 1Y
- -59.9%
- 5Y
- -91.9%
52-week range
Day change +$0.03 (+0.8%) from $3.77 to $3.80 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in NUS, bought on each weekday since 2021.
News & filings
What Nu Skin Enterprises filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockStrengthReturn on equity rose from -22.5% to 19.9% between fiscal 2024 and fiscal 2025.
Concerns (1)
- The price is 35.5% below its 200-day average, and the 50-day average is below the 200-day.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Nu Skin Enterprises, Inc., together with its subsidiaries, engages in the development and distribution of various beauty and wellness products worldwide.
Read moreShow less
Nu Skin Enterprises, Inc., together with its subsidiaries, engages in the development and distribution of various beauty and wellness products worldwide. It offers skin care devices, cosmetics, and other personal care products, including ageLOC LumiSpa, ageLOC LumiSpa iO, and Nu Skin RenuSpa iO; ageLOC TruFace and ageLOC LumiSpa cleansers and devices; Prysm iO, a data-enabled wellness device; and Nutricentials beauty and Beauty Focus wellness brands. The company also provides wellness products, such as ageLOC TRME, LifePak, and Beauty Focus. In addition, it is the research and product development of skin care products, nutritional supplements, and devices. The company sells its products under the Nu Skin, Pharmanex, and ageLOC brands through retail stores, website, digital platforms, and independent direct sellers and marketers, as well as a service center and independent marketers. It serves Mainland China; South Korea; Southeast Asia/Pacific, which includes Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Australia, New Zealand and other markets; Americas, comprising Canada, Latin America and the United States; Japan; Hong Kong/Taiwan, consists of Macau; and Europe & Africa, which includes markets in Europe as well as South Africa. Nu Skin Enterprises, Inc. was founded in 1984 and is headquartered in Provo, Utah.
- Sector
- Consumer Defensive
- Shares outstanding
- 48.2M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $258.3M
- P/E
- 1.6x
- P/B
- 0.3x
- EV / EBITDA
- 1.2x
- EV / Sales
- 0.2x
- P/S
- 0.2x
- 52-week high
- $11.54
- 52-week low
- $3.77
Profitability
- Operating margin
- 6.1%
- Net margin
- 10.8%
- EBITDA margin
- 17.7%
- ROE
- 19.9%
- ROCE
- 20.4%
- ROIC
- 19.7%
- ROA
- 11.4%
- Asset turnover
- 1.06
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $1.5B
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -14.3%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- -12.6%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -209.3%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- $46.0M
Solvency
- Current ratio
- 2.08
- Debt / Equity
- 0.38
- Debt / Assets
- 0.22
- CFO / Net profit
- 0.50
- Cash / Market cap
- 92.9%
Where the revenue went
Of every $100 of FY2025 revenue, $11 was left as net income.
| From | To | Amount |
|---|---|---|
| Revenue | Cost of revenue | $453.8M |
| Revenue | Gross profit | $1.0B |
| Gross profit | Selling, general and administrative | $940.5M |
| Gross profit | Other operating expenses | $0.00 |
| Gross profit | Operating income | $90.9M |
| Operating income | Pretax income | $90.9M |
| Interest and other income | Pretax income | $105.3M |
| Pretax income | Tax and other | $36.0M |
| Pretax income | Net income | $160.2M |
Revenue and net profit
Revenue fell 14.3% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $2.2B | $104.8M |
| FY2023 | $2.0B | $8.6M |
| FY2024 | $1.7B | -$146.6M |
| FY2025 | $1.5B | $160.2M |
Cash flows
FY2025: $80.3M from operations, $46.0M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | $108.1M | $49.0M |
| FY2023 | $118.6M | $60.1M |
| FY2024 | $111.7M | $70.2M |
| FY2025 | $80.3M | $46.0M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $1.5B-14.3%1Y
- EBITDA
- $262.4M
- Net profit
- $160.2M
- Cash from operations
- $80.3M-28.2%1Y
- Free cash flow
- $46.0M-34.4%1Y
- Revenue CAGR, 3Y
- -12.6%
- Net profit CAGR, 3Y
- 15.2%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $1.5B | $262.4M | $160.2M | $46.0M | 19.9% | -14.3% | -209.3% |
Monthly returns
Month-by-month returns of NUS across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $1.4B |
| Current assets | $547.7M |
| Non-current assets | $857.6M |
| Liabilities | $600.1M |
| Current liabilities | $263.7M |
| Non-current liabilities | $336.3M |
| Equity | $805.2M |
| Paid-in capital | $636.0M |
| Retained earnings | $1.9B |
| Treasury stock | $1.6B |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Consumer Defensive companies placed by value, growth and quality; NUS highlighted.
P/E against peers
NUS trades at 1.6x earnings against a peer median of 14.5x (a 89% discount).
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Nu Skin Enterprises, Inc.NUSthis companyP/E ↓ discount | $258.3M | 1.6x | 0.3x | 19.9% | 1.2x |
| USANA Health Sciences, Inc.USNA | $334.7M | 31.1x | 0.6x | 2.0% | 2.4x |
| B&G Foods, Inc.BGS | $320.6M | — | 0.7x | -9.6% | 12.0x |
| European Wax Center, Inc.EWCZ | $319.1M | 36.8x | 4.0x | 11.0% | 9.9x |
| Alico, Inc.ALCO | $299.8M | -2.0x | 2.9x | -143.0% | -78.1x |
| Franklin Covey Co.FC | $269.7M | 87.9x | 4.0x | 4.6% | 15.2x |
| Forafric Global PLCAFRI | $268.3M | -18.0x | -30.9x | 171.4% | 40.6x |
| Waldencast plcWALD | $224.5M | — | 0.4x | -49.7% | — |
| Limoneira CompanyLMNR | $214.9M | -13.4x | 1.3x | -9.9% | -28.0x |
| Peer median | — | 14.5x | 1.0x | -3.8% | 9.9x |
Year-to-date ROI
NUS since 1 January, against earlier years.
Historical volatility
NUS's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | 7.2% |
| FY2023 | 3.5% |
| FY2024 | 2.9% |
| FY2025 | 6.1% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $1.5B |
| Cost of revenueCost Of Revenue | $453.8M |
| Gross profitGross Profit | $1.0B |
| Operating expensesOperating Expense | $940.5M |
| Selling, general and administrativeSelling General And Administration | $940.5M |
| Total expensesTotal Expenses | $1.4B |
| Operating incomeOperating Income | $90.9M |
| Interest and other | |
| Pretax incomePretax Income | $196.2M |
| TaxTax Provision | $36.0M |
| Net incomeNet Income | $160.2M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $1.4B |
| Current assetsCurrent Assets | $547.7M |
| Non-current assetsTotal Non Current Assets | $857.6M |
| LiabilitiesTotal Liabilities Net Minority Interest | $600.1M |
| Current liabilitiesCurrent Liabilities | $263.7M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $336.3M |
| EquityTotal Equity Gross Minority Interest | $805.2M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $80.3M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $80.3M |
| Depreciation and amortisationDepreciation And Amortization | $52.3M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $52.3M |
| Stock-based compensationStock Based Compensation | $24.1M |
| Deferred taxDeferred Tax | $20.0k |
| Deferred income taxDeferred Income Tax | $20.0k |
| Operating gains and lossesOperating Gains Losses | -$169.9M |
| Gain loss on sale of businessGain Loss On Sale Of Business | -$176.2M |
| Unrealized gain loss on investment securitiesUnrealized Gain Loss On Investment Securities | $28.1M |
| Net foreign currency exchange gain lossNet Foreign Currency Exchange Gain Loss | $6.1M |
| Earnings losses from equity investmentsEarnings Losses From Equity Investments | — |
| Asset impairmentAsset Impairment Charge | $28.9M |
| Change in working capitalChange In Working Capital | -$69.6M |
| Other non-cash itemsOther Non Cash Items | $26.2M |
| Investing cash flowInvesting Cash Flow | $170.7M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | $170.7M |
| Capital expenditureCapital Expenditure | -$34.3M |
| Purchase of PP&EPurchase Of PPE | -$34.3M |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$34.3M |
| AcquisitionsPurchase Of Business | $0.00 |
| DisposalsSale Of Business | $193.7M |
| Net acquisitions and disposalsNet Business Purchase And Sale | $193.7M |
| Purchase of investmentsPurchase Of Investment | $0.00 |
| Sale of investmentsSale Of Investment | $10.2M |
| Net investment purchases and salesNet Investment Purchase And Sale | $10.2M |
| Other investing changesNet Other Investing Changes | $1.0M |
| Financing cash flowFinancing Cash Flow | -$202.4M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | -$202.4M |
| Debt issuedIssuance Of Debt | $55.0M |
| Debt repaidRepayment Of Debt | -$227.2M |
| Net debt issuedNet Issuance Payments Of Debt | -$172.2M |
| Long-term debt issuedLong Term Debt Issuance | $55.0M |
| Long-term debt repaidLong Term Debt Payments | -$227.2M |
| Net long-term debt issuedNet Long Term Debt Issuance | -$172.2M |
| Net common stock issuedNet Common Stock Issuance | -$20.0M |
| Common stock repurchasedCommon Stock Payments | -$20.0M |
| Share buybacksRepurchase Of Capital Stock | -$20.0M |
| Stock options exercisedProceeds From Stock Option Exercised | -$1.9M |
| Dividends paidCash Dividends Paid | -$11.8M |
| Common dividends paidCommon Stock Dividend Paid | -$11.8M |
| Other financing chargesNet Other Financing Charges | $3.6M |
| Change in cashChanges In Cash | $48.5M |
| Effect of exchange ratesEffect Of Exchange Rate Changes | 320.0% |
| Cash at the start of the yearBeginning Cash Position | $186.9M |
| Cash at the end of the yearEnd Cash Position | $238.6M |
| Free cash flowFree Cash Flow | $46.0M |
Learn while you research
Academy chapters picked for Nu Skin Enterprises, Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Value InvestingA P/E of 1.6 could be a value opportunity, or a value trap. Know the difference.7 min read
- 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 04 Cyclical vs Defensive StocksConsumer staples behave defensively across the business cycle.6 min read
- 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read